Human iPSC-derived Gaucher and Parkinson’s disease model in glutamatergic neurons
Western blot experiment confirmed the presence of the GBA protein in human iPSC-derived Glutamatergic Neurons
Immunofluorescent staining on GBA mutated human iPSC-derived glutamatergic neurons
Structural neuronal networks in GBA mutated human iPSC-derived glutamatergic neurons
Gene expression analysis on GBA-mutated human iPSC-derived glutamatergic neurons
Gene expression analysis between wild-type and GBA-mutated excitatory neurons
Commercially available disease models with optimized seeding density, a visual representation.
Human iPSC-derived Gaucher and Parkinson’s disease model in glutamatergic neurons
Western blot experiment confirmed the presence of the GBA protein in human iPSC-derived Glutamatergic Neurons
Immunofluorescent staining on GBA mutated human iPSC-derived glutamatergic neurons
Structural neuronal networks in GBA mutated human iPSC-derived glutamatergic neurons
Gene expression analysis on GBA-mutated human iPSC-derived glutamatergic neurons
Gene expression analysis between wild-type and GBA-mutated excitatory neurons
Commercially available disease models with optimized seeding density, a visual representation.

cat no | io1007

ioGlutamatergic Neurons GBA null/R159W

Human iPSC-derived Gaucher and Parkinson’s disease model

  • Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days

  • Engineered to carry a GBA mutation relevant for modelling Gaucher and Parkinson's diseases

  • Consistent, functional excitatory neurons that form neuronal networks within days

Place your order

Human iPSC-derived Gaucher and Parkinson’s disease model in glutamatergic neurons

Human iPSC-derived Gaucher and Parkinson’s disease model

Western blot experiment confirmed the presence of the GBA protein in human iPSC-derived Glutamatergic Neurons

GBA protein is present in ioGlutamatergic Neurons GBA null/R159W at a lower level than the wild type control

A Western blot experiment confirmed the presence of the GBA protein in ioGlutamatergic Neurons GBA null/R159W at a lower level than in the wild-type ioGlutamatergic Neurons. Day 11 cell lysates were subjected to Western blotting (20 µg protein in 40 µl per lane) using 4-20% mini protean TGX stain-free gels. Proteins were transferred onto PVDF membranes using the Trans-Blot Turbo Transfer Pack, blocked for 10 minutes, incubated with primary antibodies (GBA Invitrogen MA5-26589, 1:2000; GAPDH Abcam ab8245, 1:5000), washed three times, incubated with HRP-labelled secondary antibodies, washed three times and signal visualised by electrochemiluminescence.
1= ioGlutamatergic Neurons (wild type), 2= ioGlutamatergic Neurons GBA null/R159W.

Immunofluorescent staining on GBA mutated human iPSC-derived glutamatergic neurons

ioGlutamatergic Neurons GBA null/R159W express neuron-specific markers comparably to the isogenic control

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons GBA null/R159W compared to the isogenic control. 100X magnification.

Structural neuronal networks in GBA mutated human iPSC-derived glutamatergic neurons

ioGlutamatergic Neurons GBA null/R159W form structural neuronal networks by day 11

ioGlutamatergic Neurons GBA null/R159W mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thawing; 100X magnification.

Gene expression analysis on GBA-mutated human iPSC-derived glutamatergic neurons

ioGlutamatergic Neurons GBA null/R159W demonstrate gene expression of neuronal and glutamatergic-specific markers following deterministic programming

Gene expression analysis demonstrates that ioGlutamatergic Neurons GBA null/R159W and the isogenic control (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Gene expression analysis between wild-type and GBA-mutated excitatory neurons

Disease-related GBA is expressed in ioGlutamatergic Neurons GBA null/R159W following deterministic programming

Gene expression analysis demonstrates that ioGlutamatergic Neurons GBA null/R159W and the isogenic control (WT Control) express the GBA gene encoding the glucocerebrosidase protein. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS, cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Commercially available disease models with optimized seeding density, a visual representation.

Industry leading seeding density

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar commercially available products. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Vial limit exceeded

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.

Human iPSC-derived Gaucher and Parkinson’s disease model

ioGlutamatergic Neurons GBA null/R159W are opti‑ox deterministically programmed excitatory neurons carrying a genetically engineered compound heterozygous mutation in the GBA gene encoding the glucocerebrosidase (GCase) enzyme. These cells offer a rapidly maturing, human cell model to investigate modulation of GCase expression.

Related Parkinson's disease model cells are available with PINK1 Q456X, PRKN R275W and SNCA A53T mutations, and all can be used alongside their genetically matched control, ioGlutamatergic Neurons.

Benchtop benefits

comparison_0

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the GBA mutation on molecular mechanisms and cell function.

scalable

Scalable

With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.

quick

Quick

The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Cells arrive ready to plate


ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons GBA null/R159W are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Product specifications

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast),
Genotype APOE 3/4

Vial size

Small: >1 x 106 viable cells, Evaluation pack**: 3 small vials of >1 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (long amplicon sequencing)

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm2

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Compound heterozygous null/R159W mutation in the GBA gene*

Applications

Gaucher and Parkinson's disease research
Drug discovery and development
Disease modelling

Product use

ioCells are for research use only

*The null allele has a 1 base heterozygous deletion at position chr1:155,238,622 (GRCh38) located in coding exon 6, causing a frameshift resulting in a series of STOP codons (ENST00000574670.5). The second allele has a missense mutation, R159W (NM_000157.4(GBA1):c.475C>T (p.Arg159Trp))

** Evaluation packs are intended for first-time users, or for existing users testing a new cell type or derivative. A user can request multiple evaluation packs as long as each one is for a different product, with only one pack allowed per product.

Technical data

Highly characterised and defined

ioGlutamatergic Neurons GBA null/R159W express neuron-specific markers comparably to the isogenic control

io1007-ioGlutamatergic-Neurons-GBA-null-R159W-ICC-TUBB3-MAP2-VGLUT2

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons GBA null/R159W compared to the isogenic control. 100X magnification.

ioGlutamatergic Neurons GBA null/R159W form structural neuronal networks by day 11

io1007-ioGlutamatergic-Neurons-GBA-null-R159W-Morphology

ioGlutamatergic Neurons GBA null/R159W mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thawing; 100X magnification.

ioGlutamatergic Neurons GBA null/R159W demonstrate gene expression of neuronal and glutamatergic-specific markers following deterministic programming

io1007_GBA_null-R159W_RT-qPCR

Gene expression analysis demonstrates that ioGlutamatergic Neurons GBA null/R159W and the isogenic control (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Disease-related GBA is expressed in ioGlutamatergic Neurons GBA null/R159W following deterministic programming

GBA null-R159W GBA

Gene expression analysis demonstrates that ioGlutamatergic Neurons GBA null/R159W and the isogenic control (WT Control) express the GBA gene encoding the glucocerebrosidase protein. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS, cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

GBA protein is present in ioGlutamatergic Neurons GBA null/R159W at a lower level than the wild type control

io1007_GBA null-R159W_western-blot

A Western blot experiment confirmed the presence of the GBA protein in ioGlutamatergic Neurons GBA null/R159W at a lower level than in the wild-type ioGlutamatergic Neurons. Day 11 cell lysates were subjected to Western blotting (20 µg protein in 40 µl per lane) using 4-20% mini protean TGX stain-free gels. Proteins were transferred onto PVDF membranes using the Trans-Blot Turbo Transfer Pack, blocked for 10 minutes, incubated with primary antibodies (GBA Invitrogen MA5-26589, 1:2000; GAPDH Abcam ab8245, 1:5000), washed three times, incubated with HRP-labelled secondary antibodies, washed three times and signal visualised by electrochemiluminescence.
1= ioGlutamatergic Neurons (wild type), 2= ioGlutamatergic Neurons GBA null/R159W.

Industry leading seeding density

ioGlutamatergic_Neurons_seeding_density_small_96_384

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar commercially available products. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

How to culture ioGlutamatergic Neurons

In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.

Product resources

(LinkedValues: [{hs_name=ioGlutamatergic Neurons Wild Type and related disease models | User Manual, hs_id=161968263487, hs_path=glutamatergic-neurons, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=bit-bio ioGlutamatergic Neurons Day 14 Beta III Tubulin staining copy, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/ioGlutamatergic%20Neurons%20in%20Drug%20Discovery/bit-bio%20ioGlutamatergic%20Neurons%20Day%2014%20Beta%20III%20Tubulin%20staining%20copy.jpeg, height=1200}, year={label=2025, value=2025}, summary=<p>DOC-1289 4.0</p> <p>bit.bio</p> <p>2025<br><br></p>, date_published=1707955200000, sort_date=1713225600000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioGlutamatergic Neurons HTT 50CAG/WT, value=ioGlutamatergic Neurons HTT 50CAG/WT}, {label=ioGlutamatergic Neurons TDP-43 M337V Het, value=ioGlutamatergic Neurons TDP-43 M337V Het}, {label=ioGlutamatergic Neurons TDP-43 M337V Hom, value=ioGlutamatergic Neurons TDP-43 M337V Hom}, {label=ioGlutamatergic Neurons MAPT P301S/WT, value=ioGlutamatergic Neurons MAPT P301S/WT}, {label=ioGlutamatergic Neurons MAPT P301S/P301S, value=ioGlutamatergic Neurons MAPT P301S/P301S}, {label=ioGlutamatergic Neurons MAPT N279K/WT, value=ioGlutamatergic Neurons MAPT N279K/WT}, {label=Product information, value=Product information}, {label=User manual, value=user_manual}], media_contact=<p><span>DOC-1289 4.0</span></p> <p><span>bit.bio</span></p> <p><span>2025</span></p>, listing_button_label=Download}, {hs_name=CRISPRa-Ready ioGlutamatergic Neurons | User Manual, hs_id=186090210329, hs_path=crispr-activation-ready-glutamatergic-neurons, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=bit.bio-CRISPRa-ready-ioGlutamatergic-neurons-map2-staining, width=856, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioGlutamatergic%20Neurons/CRISPRa-Ready%20ioGlutamatergic%20Neurons/bit.bio-CRISPRa-ready-ioGlutamatergic-neurons-map2-staining.png, height=856}, year={label=2025, value=2025}, summary=V1<br>2025<br>bit.bio, date_published=1739404800000, sort_date=1739404800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=Product information, value=Product information}, {label=CRISPRa-Ready ioGlutamatergic Neurons, value=crispra-ready_ioglutamatergic_neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=User manual, value=user_manual}], media_contact=V1<br>2025<br>bit.bio, listing_button_label=Download}, {hs_name=CRISPRi-Ready ioGlutamatergic Neurons | User Manual, hs_id=186807423031, hs_path=crispri-ready-ioglutamatergic-neurons-user-manual, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=bit.bio-io1098-CRISPRi-ready-glutamatergic-neurons-tubb3-staining, width=856, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioGlutamatergic%20Neurons/CRISPRi-Ready%20ioGlutamatergic%20Neurons/bit.bio-io1098-CRISPRi-ready-glutamatergic-neurons-tubb3-staining.png, height=796}, year={label=2025, value=2025}, summary=V1<br>2025<br>bit.bio, date_published=1740960000000, sort_date=1740960000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=Product information, value=Product information}, {label=User manual, value=user_manual}], media_contact=V1<br>2025<br>bit.bio, listing_button_label=Download}, {hs_name=Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells, hs_id=161968263519, hs_path=modelling-neurodevelopment-webinar-2022, button_label=Explore ioGlutamatergic Neurons, button_link=https://www.bit.bio/products/nerve-cells/glutamatergic-neurons-wild-type-io1001, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/BitBio2022/product-page/Colour%20webinar%20with%2060x%20Map2-com.jpg, height=732}, year={label=2022, value=2022}, summary=<p><span>Dr Deepak Srivastava | King’s College London<br><br></span><span></span></p>, date_published=1707436800000, sort_date=1649376000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=Webinars , value=webinars}, {label=Webinar | Modelling neurodevelopment , value=webinar_|_modelling_neurodevelopment}, {label=ioGABAergic Neurons!, value=iogabaergic_neurons}], media_contact=null, listing_button_label=Watch now}, {hs_name=Rethinking Developmental Biology With Cellular Reprogramming, hs_id=161968263524, hs_path=rethinking-developmental-biology-with-cellular-reprogramming, button_label=Explore ioCells, button_link=https://www.bit.bio/discover-iocells, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1860, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Upcoming%20Webinars/Tech%20Nets%202023/bit.bio_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png, height=1260}, year={label=2023, value=2023}, summary=<p>Mark Kotter | CEO and founder | bit.bio</p> <p>Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |&nbsp; Stanford University</p>, date_published=1709164800000, sort_date=1681776000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioMicroglia, value=ioMicroglia}, {label=Cell therapy, value=Cell therapy}, {label=ioSensory Neurons, value=ioSensory Neurons}, {label=ioOligodendrocyte-like cells, value=ioOligodendrocyte-like cells}, {label=Webinars , value=webinars}, {label=Webinar | Rethinking Developmental Biology, value=webinar_|_rethinking_developmental_biology}, {label=ioGABAergic Neurons!, value=iogabaergic_neurons}], media_contact=null, listing_button_label=Watch now}, {hs_name=Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming, hs_id=161968263525, hs_path=addressing-the-reproducibility-crisis-driving-genome-wide-consistency-in-cellular-reprogramming, button_label=Explore ioCells, button_link=https://www.bit.bio/discover-iocells, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1860, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Upcoming%20Webinars/Tech%20Nets%2019th%20July%202023/bit.bio_ioGlutamatergic%20Neurons_60xMAP2(red)Hoescht(blue)TUBB3(blue)_day4.jpg, height=1260}, year={label=2023, value=2023}, summary=<p>Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio</p>, date_published=1709769600000, sort_date=1689724800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioSensory Neurons, value=ioSensory Neurons}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=Webinars , value=webinars}, {label=Webinar | Addressing the Reproducibility Crisis, value=webinar Addressing the Reproducibility Crisis}], media_contact=null, listing_button_label=Watch now}, {hs_name=Running Large-Scale CRISPR Screens in Human Neurons, hs_id=161968263528, hs_path=running-large-scale-crispr-screens-in-human-neurons, button_label=null, button_link=null, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Emails/Header%20images/Header%20Images%20-%20ICC%20only/Running%20Large-Scale%20CRISPR%20Screens%20in%20Human%20Neurons_email%20header.png, height=678}, year={label=2023, value=2023}, summary=<p>Emmanouil Metzakopian | Vice President, Research and Development | bit.bio</p> <p>Javier Conde-Vancells | Director Product Management | bit.bio</p>, date_published=1710460800000, sort_date=1700524800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=CRISPR-Ready ioMicroglia, value=CRISPR-Ready ioMicroglia}, {label=Webinars , value=webinars}, {label=Webinar Running Large-Scale CRISPR Screens, value=webinar_running_large-scale_crispr_screens}], media_contact=null, listing_button_label=Watch now}, {hs_name=Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease, hs_id=183096620633, hs_path=human-ipsc-based-models-of-glial-cells-for-studying-neurodegenerative-disease, button_label=null, button_link=null, type={label=Webinar, value=Webinar}, thumbnail={alt_text=bitbio-oligodendrocyte-like-cells-O4-MBP-immunocytochemistry, width=1000, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioOligodendrocyte-like%20cells/bitbio-oligodendrocyte-like-cells-O4-MBP-immunocytochemistry.jpg, height=1350}, year={label=2024, value=2024}, summary=Valentina Fossati, PhD | Senior Research Investigator | The New York Stem Cell Foundation<br><br>Inês Ferreira | Senior Product Manager | bit.bio, date_published=1732233600000, sort_date=1732233600000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioOligodendrocyte-like cells, value=ioOligodendrocyte-like cells}, {label=Webinars , value=webinars}, {label=Webinar | Human iPSC-Based Models of Glial , value=webinar_|_human_ipsc-based_models_of_glial}], media_contact=null, listing_button_label=Watch now}])
CRISPRi-Ready ioGlutamatergic Neurons | User Manual User manual
CRISPRi-Ready ioGlutamatergic Neurons | User Manual
V1
2025
bit.bio
Download
CRISPRa-Ready ioGlutamatergic Neurons | User Manual User manual
CRISPRa-Ready ioGlutamatergic Neurons | User Manual
V1
2025
bit.bio
Download
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease Webinar
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease
Valentina Fossati, PhD | Senior Research Investigator | The New York Stem Cell Foundation

Inês Ferreira | Senior Product Manager | bit.bio
Watch now
ioGlutamatergic Neurons Wild Type and related disease models | User Manual User manual
ioGlutamatergic Neurons Wild Type and related disease models | User Manual

DOC-1289 4.0

bit.bio

2025

Download
Running Large-Scale CRISPR Screens in Human Neurons Webinar
Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming Webinar
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio

Watch now
Rethinking Developmental Biology With Cellular Reprogramming Webinar
Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells Webinar
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells

Dr Deepak Srivastava | King’s College London

Watch now

Cell culture hacks | human iPSC-derived glutamatergic neurons

Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.

bit.bio_3x2_ioGlutamatergic Neurons_MAP2_Hoescht_x20_hi.res (1)

Wild Type and Isogenic Disease Model cells: A true comparison.

Further your disease research by pairing our wild type cells with isogenic disease models.

bitbio-vials-Wild_and_Disease-staggered-2500px_wide

ioCells catalogue

Human iPSC-derived cells

powered by opti-ox

Consistent. Defined. Scalable.

bitbio-cell_catalogue_header-with-tracker-Desktop-2500x1664